CD19 and neoplasm: In “targeted, non-tumor” toxicity, T cells target normal tissue cells that express tumor-associated antigens, such as B-cell aplastic anemia observed with CD19 CAR, and pulmonary edema caused by ERBB2 CAR (Chen et al., 2022).